PEB's Principal Activity is the development and deployment of specialist cancer diagnostics tools.
Last (Price) | |
Change | 0.00 (0.00) |
Bid / Ask | - |
Volume | |
Volume (4w avg) | |
Turnover | |
Open | |
Day Range | - |
VWAP | |
Prev Close | |
Last Trade |
1 Week | |
1 Month | |
2022 YTD | |
1 Year | |
vs Sector (1yr) | - |
vs ASX 200 (1yr) | -54.42% |
Date | Heading | Pages | File Size | Time |
---|---|---|---|---|
Pacific Edge Limited (PEB) is a cancer diagnostics company. It is being in to discovering, building and commercialising innovative cancer diagnostic tests that can contribute to a clinically meaningful difference in the detection and management of cancer.
No incorporation details available.
Head Office | Dunedin New Zealand 9016 |
Website | www.pacificedgedx.com |
Registry | Link Market Services |
Auditor | PricewaterhouseCoopers |
Date Listed | 27 Sep 2021 |
Date | Event |
---|---|
24/11/2022 | Report (Interim) |
DPS and Yield calculations use the Pay Date.
See Upcoming Dividends for all ASX companies.
PEB directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
The current holdings of PEB directors.
No Substantial Shareholders for PEB in our database.
12 month transaction history compiled from ASX announcements.
No buy transactions reported by Substantial Shareholders in the past 12 months.
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
Date | Close | Change | %Chg | Open | High | Low | Volume | Turnover |
---|---|---|---|---|---|---|---|---|
Year | Closing Price | Last Trade |
---|---|---|
No Financial Year End data available |
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.